Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Long-term cardiovascular outcomes in patients with lymphoma who had early post-CAR-T cardiovascular events: A multi-center, international study

Blood (2025) 146 (Supplement 1): 3723.

https://doi.org/10.1182/blood-2025-3723

Published: 2025

Journal Articles

First-line salvage therapies in relapsed/refractory large B-cell lymphoma after second- or third-line CD19-directed CAR T-cell therapy

Blood (2025) 146 (Supplement 1): 3711.

https://doi.org/10.1182/blood-2025-3711

Published: 2025

Journal Articles

Tumor mutational burden as a novel biomarker of resistance to CD19 CAR-T cell therapy in large B-cell lymphoma

Blood (2025) 146 (Supplement 1): 565.

https://doi.org/10.1182/blood-2025-565

Published: 2025

Journal Articles

Central nervous system involvement in Mantle Cell Lymphoma: A retrospective multicenter cohort study from the spanish geltamo group

Mariana Bastos-Oreiro, Alba Cabirta, Amanda Perez, Ana Saus Carreres, Sonia González De Villambrosia, Marta Canelo, Ana Maria Garcia-Noblejas Moya, Beatriz De La Cruz Benito, Paola Villafuerte Gutiérrez, Fatima De la Cruz Vicente, Juan Carlos Caballero, Ana Jiménez-Ubieto, Daniel García Belmonte, Ana Muntanola Prat, Eva Gonzalez Barca, Hugo Daniel Luzardo Henríquez, Eduardo Rios Herranz, Alejandro Martin Garcia-Sancho, Carlos Grande, Concepción Nicolás, Antonio Gutierrez, Marina Gomez-Llobell, Jose Angel Hernandez Rivas, Blanca Sánchez-González, Ainara Ferrero Campos, Rosalia Alonso Trillo, Eva Donato, Silvia Rocio Verdesoto Cozzarelli, Sandra Suarez Ordoñez, Emilia Pardal De La Mano, Pilar Gomez Prieto, Amparo Avaría, Lucia Villalon Blanco, Alicia Roldán-Pérez, Raul Cordoba, Juan-Manuel Sancho, Eva Gine, Víctor Navarro Garces, Pau Abrisqueta, Ana Marin Niebla

Blood (2025) 146 (Supplement 1): 3585.

https://doi.org/10.1182/blood-2025-3585

Published: 2025

Journal Articles

The simple c-reactive protein (CRP) to albumin ratio (CAR) stratifies treatment response and survival following chimeric antigen receptor T-cell therapy for non-Hodgkin's lymphoma

Blood (2025) 146 (Supplement 1): 7090.

https://doi.org/10.1182/blood-2025-7090

Published: 2025

Journal Articles

Respiratory viral infections are a significant cause of morbidity during long-term follow-up after CAR T cell therapy: Analysis of 445 episodes

Blood (2025) 146 (Supplement 1): 4498.

https://doi.org/10.1182/blood-2025-4498

Published: 2025

Journal Articles

Pre-existing cognitive impairment is associated with reduced long-term survival following chimeric antigen receptor T-cell therapy for non-Hodgkin's lymphoma

Blood (2025) 146 (Supplement 1): 6296.

https://doi.org/10.1182/blood-2025-6296

Published: 2025

Journal Articles

Respiratory syncytial virus (RSV) infection after CAR T-cell therapy

Blood (2025) 146 (Supplement 1): 1079.

https://doi.org/10.1182/blood-2025-1079

Published: 2025

Journal Articles

Detection of intratumoral microorganisms in DLBCL impacts on CART-cell outcomes

Blood (2025) 146 (Supplement 1): 5341.

https://doi.org/10.1182/blood-2025-5341

Published: 2025

Journal Articles

Comprehensive genomic profiling of diffuse large B cell lymphoma using targeted NGS: Insights into MYC, BCL2, and BCL6 rearrangements and beyond

Sara Fernánez de Córdoba, Mariana Bastos-Oreiro, Francisco Diaz Crespo, Ismael De La Iglesia San Sebastián, María Chicano, Juan Carlos Triviño, Marina Gomez-Llobell, Paula Fernandez-Caldas, Pablo Silva, Raquel Fernandez, Javier Menarguez, Ramon Garcia-Sanz, Ismael Buño, Carolina Martinez-Laperche

Blood (2025) 146 (Supplement 1): 5310.

https://doi.org/10.1182/blood-2025-5310

Published: 2025

Journal Articles

Plasmablastic lymphoma (PBL) comparison between europe - Latin America and validation of the PBL international prognostic index (PBL-IPI): Collaborative study of the lymphoma groups geltamo, gatla and gell

Blood (2025) 146 (Supplement 1): 899.

https://doi.org/10.1182/blood-2025-899

Published: 2025

Journal Articles

Impact of holding therapy prior to apheresis on outcomes following CD19 CAR-T cell therapy in large B-cell lymphoma

Blood (2025) 146 (Supplement 1): 6328.

https://doi.org/10.1182/blood-2025-6328

Published: 2025

Journal Articles

Safety and efficacy of brexucabtagene autoleucel in elderly patients with relapsed or refractory Mantle Cell Lymphoma: A retrospective, multicenter, international study

Blood (2025) 146 (Supplement 1): 2710.

https://doi.org/10.1182/blood-2025-2710

Published: 2025

Journal Articles

Impact of bridging therapies prior to CAR T cell therapy for large B-cell lymphoma: Real-world analysis from the cell therapy consortium

Alexandra Rojek, Alyssa Gibson, Marina Gomez-Llobell, Miguel-Angel Perales, Joseph McGuirk, Stephen Schuster, David Porter, Jamie Brower, Hanan Alharthy, Sairah Ahmed, Richard Maziarz, Veronika Bachanova, Olalekan Oluwole, Anthony Hunter, Peter Riedell

Blood (2025) 146 (Supplement 1): 2707.

https://doi.org/10.1182/blood-2025-2707

Published: 2025

Journal Articles

BTKi in the peri-infusion period in lymphoma patients receiving CD19 CAR T cell therapy

Blood (2025) 146 (Supplement 1): 4492.

https://doi.org/10.1182/blood-2025-4492

Published: 2025

Journal Articles

T-ICAHT: grading and prognostic impact of thrombocytopenia after CAR T-cell therapy

Blood (2025) 146 (7): 834–846.

https://doi.org/10.1182/blood.2025028833

Published: 2025

Includes: Supplemental data

Journal Articles

CAR-Tography: Longitudinal Mapping of CAR-T Toxicities across B-Cell Malignancies Reveals Biologically Distinct and Prognostically Relevant Toxicity Phenotypes

Blood (2024) 144 (Supplement 1): 912.

https://doi.org/10.1182/blood-2024-203520

Published: 2024

Journal Articles

Patterns of Immune Reconstitution and Their Clinical Significance in Aggressive Lymphoma Treated with CAR-T Therapy

Blood (2024) 144 (Supplement 1): 2034.

https://doi.org/10.1182/blood-2024-205548

Published: 2024

Journal Articles

A New Prognostic Index Including Baseline Clinico-Biological Variables Predicts Outcome in Plasmablastic Neoplasms

Blood (2024) 144 (Supplement 1): 4478.

https://doi.org/10.1182/blood-2024-212008

Published: 2024

Journal Articles

Integration of Geriatric Assessment and Genetic Profile Facilitates Personalized Treatment Selection and Follow-up in Old Patients with Newly Diagnosed Acute Myeloid Leukemia

Pilar Lancho Lavilla, Miguel Lopez-Esteban, Javier Ortiz-Alonso, Gracia Fajardo-Tórtola, Patricia Font Lopez, Marina Gomez Llobell, Jose Antonio Serra Resach, Ana Perez-Corral, Isabel Regalado Artamendi, Mónica Ballesteros Andrés, Carolina Martinez-Laperche, Gloria Figaredo Garcia-Mina, Raquel Fernández González, Carlos Jiménez, Diego Conde Royo, Cristina Pascual Izquierdo, María Teresa Vidán, Ramon García-Sanz, Gabriela Rodriguez Macias

Blood (2024) 144 (Supplement 1): 5050.

https://doi.org/10.1182/blood-2024-203872

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Date

Availability

Long-term cardiovascular outcomes in patients with lymphoma who had early post-CAR-T cardiovascular events: A multi-center, international study

First-line salvage therapies in relapsed/refractory large B-cell lymphoma after second- or third-line CD19-directed CAR T-cell therapy

Tumor mutational burden as a novel biomarker of resistance to CD19 CAR-T cell therapy in large B-cell lymphoma

Central nervous system involvement in Mantle Cell Lymphoma: A retrospective multicenter cohort study from the spanish geltamo group

The simple c-reactive protein (CRP) to albumin ratio (CAR) stratifies treatment response and survival following chimeric antigen receptor T-cell therapy for non-Hodgkin's lymphoma

Respiratory viral infections are a significant cause of morbidity during long-term follow-up after CAR T cell therapy: Analysis of 445 episodes

Pre-existing cognitive impairment is associated with reduced long-term survival following chimeric antigen receptor T-cell therapy for non-Hodgkin's lymphoma

Respiratory syncytial virus (RSV) infection after CAR T-cell therapy

Detection of intratumoral microorganisms in DLBCL impacts on CART-cell outcomes

Comprehensive genomic profiling of diffuse large B cell lymphoma using targeted NGS: Insights into MYC, BCL2, and BCL6 rearrangements and beyond

Plasmablastic lymphoma (PBL) comparison between europe - Latin America and validation of the PBL international prognostic index (PBL-IPI): Collaborative study of the lymphoma groups geltamo, gatla and gell

Impact of holding therapy prior to apheresis on outcomes following CD19 CAR-T cell therapy in large B-cell lymphoma

Safety and efficacy of brexucabtagene autoleucel in elderly patients with relapsed or refractory Mantle Cell Lymphoma: A retrospective, multicenter, international study

Impact of bridging therapies prior to CAR T cell therapy for large B-cell lymphoma: Real-world analysis from the cell therapy consortium

BTKi in the peri-infusion period in lymphoma patients receiving CD19 CAR T cell therapy

T-ICAHT: grading and prognostic impact of thrombocytopenia after CAR T-cell therapy

CAR-Tography: Longitudinal Mapping of CAR-T Toxicities across B-Cell Malignancies Reveals Biologically Distinct and Prognostically Relevant Toxicity Phenotypes

Patterns of Immune Reconstitution and Their Clinical Significance in Aggressive Lymphoma Treated with CAR-T Therapy

A New Prognostic Index Including Baseline Clinico-Biological Variables Predicts Outcome in Plasmablastic Neoplasms

Integration of Geriatric Assessment and Genetic Profile Facilitates Personalized Treatment Selection and Follow-up in Old Patients with Newly Diagnosed Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only